These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 14641996)

  • 1. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation.
    Wehner M; Rueffert H; Koenig F; Neuhaus J; Olthoff D
    Clin Genet; 2002 Aug; 62(2):135-46. PubMed ID: 12220451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4-chloro-m-cresol in human myotubes.
    Wehner M; Rueffert H; Koenig F; Meinecke CD; Olthoff D
    Cell Calcium; 2003 Aug; 34(2):163-8. PubMed ID: 12810058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility.
    Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM
    Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated resting [Ca(2+)](i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR.
    Yang T; Esteve E; Pessah IN; Molinski TF; Allen PD; López JR
    Am J Physiol Cell Physiol; 2007 May; 292(5):C1591-8. PubMed ID: 17182726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
    Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
    Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia.
    Johannsen S; Treves S; Müller CR; Mögele S; Schneiderbanger D; Roewer N; Schuster F
    Neuromuscul Disord; 2016 Jan; 26(1):21-5. PubMed ID: 26631338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of human cultured myotubes responses mediated by ryanodine receptor 1.
    Kobayashi M; Mukaida K; Migita T; Hamada H; Kawamoto M; Yuge O
    Anaesth Intensive Care; 2011 Mar; 39(2):252-61. PubMed ID: 21485675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
    Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.
    Kondo T; Yasuda T; Mukaida K; Otsuki S; Kanzaki R; Miyoshi H; Hamada H; Nishino I; Kawamoto M
    J Anesth; 2018 Apr; 32(2):174-181. PubMed ID: 29344738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1).
    Haraki T; Yasuda T; Mukaida K; Migita T; Hamada H; Kawamoto M
    Anesth Analg; 2011 Dec; 113(6):1461-7. PubMed ID: 21926372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.
    Kaufmann A; Kraft B; Michalek-Sauberer A; Weindlmayr M; Kress HG; Steinboeck F; Weigl LG
    Anesth Analg; 2012 May; 114(5):1017-25. PubMed ID: 22415532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.
    Tong J; Oyamada H; Demaurex N; Grinstein S; McCarthy TV; MacLennan DH
    J Biol Chem; 1997 Oct; 272(42):26332-9. PubMed ID: 9334205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1.
    Dirksen RT; Avila G
    Biophys J; 2004 Nov; 87(5):3193-204. PubMed ID: 15347586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
    Eltit JM; Bannister RA; Moua O; Altamirano F; Hopkins PM; Pessah IN; Molinski TF; López JR; Beam KG; Allen PD
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7923-8. PubMed ID: 22547813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1).
    Du GG; Oyamada H; Khanna VK; MacLennan DH
    Biochem J; 2001 Nov; 360(Pt 1):97-105. PubMed ID: 11695996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
    Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG
    Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.